{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:10:14Z","timestamp":1793261414878,"version":"4.5.0"},"reference-count":69,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"\n Importance<\/jats:title>\n Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP mAbs) offer effective migraine-specific preventive treatment. However, concerns exist about their potential cardiovascular risks due to CGRP blockade.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the incidence of cardiovascular disease (CVD) between Medicare beneficiaries with migraine who initiated anti-CGRP-mAbs vs onabotulinumtoxinA in the US.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective, sequential cohort study was conducted among a nationally representative population-based sample of Medicare claims from May 2018 through December 2020. Data analysis was performed from August to December 2023. This study included fee-for-service Medicare beneficiaries aged 18 years or older with migraine who initiated either anti-CGRP mAbs or onabotulinumtoxinA. Beneficiaries who had a history of myocardial infarction (MI), stroke, cluster headache, malignant cancer, or hospice service within a 1-year baseline period prior to treatment initiation were excluded. To minimize channeling bias from new drug introductions and time-related bias due to the COVID-19 pandemic, 5 cohorts were established, representing sequential 6-month calendar intervals based on the initial prescription or date of index anti-CGRP mAbs or onabotulinumtoxinA use.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Anti-CGRP mAbs vs onabotulinumtoxinA.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was time to first MI or stroke. Secondary outcomes included hypertensive crisis, peripheral revascularization, and Raynaud phenomenon. The inverse probability of treatment-weighted Cox proportional hazards models were used to compare outcomes between the 2 treatment groups.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 266\u202f848 eligible patients with migraine, 5153 patients initiated anti-CGRP mAbs (mean [SD] age, 57.8 [14.0] years; 4308 female patients [83.6%]) and 4000 patients initiated onabotulinumtoxinA (mean [SD] age, 61.9 [13.7] years; 3353 female patients [83.8%]). Use of anti-CGRP mAbs was not associated with an increased risk of composite CVD events (adjusted hazard ratio [aHR], 0.88; 95% CI, 0.44-1.77), hypertensive crisis (aHR, 0.46; 95% CI, 0.14-1.55), peripheral revascularization (aHR, 1.50; 95% CI, 0.48-4.73), or Raynaud phenomenon (aHR, 0.75; 95% CI, 0.45-1.24) compared with onabotulinumtoxinA. Subgroup analyses by age group and presence of established non-MI or stroke CVD showed similar findings.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, despite initial concerns regarding the cardiovascular effects of CGRP blockade, anti-CGRP mAbs were not associated with an increased risk of CVD compared with onabotulinumtoxinA among adult Medicare beneficiaries with migraine, who were predominantly older adults or individuals with disability. Future studies with longer follow-up periods and in other populations are needed to confirm these findings.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.4537","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T11:01:42Z","timestamp":1736161302000},"page":"132","source":"Crossref","is-referenced-by-count":31,"title":["Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine"],"prefix":"10.1001","volume":"82","author":[{"given":"Seonkyeong","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Orlova","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesuk","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"Center For Integrative Cardiovascular and Metabolic Disease, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Chapin","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, School of Medicine, University of Florida, Gainesville"},{"name":"Geriatric Research Education and Clinical Center, North Florida\/South Georgia Veterans Health System, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie L.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hsuan","family":"Lo-Ciganic","sequence":"additional","affiliation":[{"name":"Geriatric Research Education and Clinical Center, North Florida\/South Georgia Veterans Health System, Gainesville, Florida"},{"name":"Division of General Internal Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"},{"name":"Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"noi240083r1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","article-title":"Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.","volume":"17","author":"GBD 2016 Headache Collaborators","year":"2018","journal-title":"Lancet Neurol"},{"issue":"1","key":"noi240083r2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","article-title":"The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates.","volume":"23","author":"Stovner","year":"2022","journal-title":"J Headache Pain"},{"issue":"7","key":"noi240083r3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","article-title":"The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice.","volume":"61","author":"Ailani","year":"2021","journal-title":"Headache"},{"issue":"1","key":"noi240083r4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.13456","article-title":"The American Headache Society position statement on integrating new migraine treatments into clinical practice.","volume":"59","author":"American Headache Society","year":"2019","journal-title":"Headache"},{"issue":"1","key":"noi240083r9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.410330109","article-title":"The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats.","volume":"33","author":"Goadsby","year":"1993","journal-title":"Ann Neurol"},{"issue":"2","key":"noi240083r10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.410280213","article-title":"Vasoactive peptide release in the extracerebral circulation of humans during migraine headache.","volume":"28","author":"Goadsby","year":"1990","journal-title":"Ann Neurol"},{"issue":"1","key":"noi240083r11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","article-title":"CGRP may play a causative role in migraine.","volume":"22","author":"Lassen","year":"2002","journal-title":"Cephalalgia"},{"issue":"5","key":"noi240083r12","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/HYPERTENSIONAHA.113.02517","article-title":"An ongoing role of a-calcitonin gene-related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress.","volume":"63","author":"Smillie","year":"2014","journal-title":"Hypertension"},{"issue":"1-3","key":"noi240083r13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejphar.2005.12.039","article-title":"The role of calcitonin gene-related peptide (CGRP) in ischemic preconditioning in isolated rat hearts.","volume":"531","author":"Chai","year":"2006","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"noi240083r14","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.bbrc.2015.06.054","article-title":"TRPV1 activation is involved in the cardioprotection of remote limb ischemic postconditioning in ischemia-reperfusion injury rats.","volume":"463","author":"Gao","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"noi240083r15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0014-2999(02)01538-8","article-title":"The cardioprotection of calcitonin gene-related peptide-mediated preconditioning.","volume":"442","author":"Li","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"noi240083r16","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1159\/000444439","article-title":"Transient receptor potential vanilloid subtype 1 inhibits inflammation and apoptosis via the release of calcitonin gene-related peptide in the heart after myocardial infarction.","volume":"134","author":"Lei","year":"2016","journal-title":"Cardiology"},{"issue":"3","key":"noi240083r17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/cvr\/24.3.239","article-title":"Improved cardiac performance with human calcitonin gene related peptide in patients with congestive heart failure.","volume":"24","author":"Gennari","year":"1990","journal-title":"Cardiovasc Res"},{"issue":"1","key":"noi240083r18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1177\/147323001204000114","article-title":"Serum levels of calcitonin gene-related peptide and substance P are decreased in patients with diabetes mellitus and coronary artery disease.","volume":"40","author":"Wang","year":"2012","journal-title":"J Int Med Res"},{"issue":"6","key":"noi240083r19","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/head.13534","article-title":"Safety and tolerability of fremanezumab for the prevention of migraine: a pooled analysis of phases 2b and 3 clinical trials.","volume":"59","author":"Silberstein","year":"2019","journal-title":"Headache"},{"issue":"1","key":"noi240083r20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/head.13684","article-title":"Evaluation of cardiovascular outcomes in adult patients with episodic or chronic migraine treated with galcanezumab: data from three phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies.","volume":"60","author":"Oakes","year":"2020","journal-title":"Headache"},{"issue":"5","key":"noi240083r21","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1212\/WNL.0000000000008743","article-title":"Vascular safety of erenumab for migraine prevention.","volume":"94","author":"Kudrow","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"noi240083r22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/head.14051","article-title":"Hypertension: a new safety risk for patients treated with erenumab.","volume":"61","author":"Saely","year":"2021","journal-title":"Headache"},{"issue":"1","key":"noi240083r23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-022-01424-w","article-title":"Calcitonin gene-related peptide-targeting drugs and Raynaud\u2019s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database.","volume":"23","author":"G\u00e9rard","year":"2022","journal-title":"J Headache Pain"},{"issue":"6","key":"noi240083r24","doi-asserted-by":"publisher","first-page":"580","DOI":"10.7861\/clinmed.2020-0754","article-title":"Raynaud\u2019s phenomenon.","volume":"20","author":"Haque","year":"2020","journal-title":"Clin Med (Lond)"},{"key":"noi240083r25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/CLEP.S105613","article-title":"Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US.","volume":"9","author":"Mues","year":"2017","journal-title":"Clin Epidemiol"},{"issue":"2","key":"noi240083r29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2217\/cer.12.12","article-title":"Newly marketed medications present unique challenges for nonrandomized comparative effectiveness analyses.","volume":"1","author":"Rassen","year":"2012","journal-title":"J Comp Effectiveness Res"},{"issue":"2","key":"noi240083r30","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/EDE.0b013e3182459d7d","article-title":"Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules.","volume":"23","author":"Gagne","year":"2012","journal-title":"Epidemiology"},{"issue":"6","key":"noi240083r31","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jacc.2022.06.008","article-title":"Impact of the COVID-19 pandemic on cardiovascular health in 2020: JACC State-of-the-Art Review.","volume":"80","author":"Roth","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"noi240083r32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40471-014-0027-z","article-title":"Misclassification in administrative claims data: quantifying the impact on treatment effect estimates.","volume":"1","author":"Funk","year":"2014","journal-title":"Curr Epidemiol Rep"},{"issue":"1","key":"noi240083r33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/pds.3310","article-title":"Validation of acute myocardial infarction in the Food and Drug Administration\u2019s Mini-Sentinel program.","volume":"22","author":"Cutrona","year":"2013","journal-title":"Pharmacoepidemiol Drug Safety"},{"issue":"7","key":"noi240083r34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253580","article-title":"Acute myocardial infarction: development and application of an ICD-10-CM-based algorithm to a large U.S. healthcare claims-based database.","volume":"16","author":"Saunders-Hastings","year":"2021","journal-title":"PLoS One"},{"key":"noi240083r35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/CLEP.S288518","article-title":"Validation of ICD-10-CM diagnosis codes for identification of patients with acute hemorrhagic stroke in a national health insurance claims database.","volume":"13","author":"Hsieh","year":"2021","journal-title":"Clin Epidemiol"},{"key":"noi240083r36","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2147\/CLEP.S273853","article-title":"Performance of ICD-10-CM diagnosis codes for identifying acute ischemic stroke in a national health insurance claims database.","volume":"12","author":"Hsieh","year":"2020","journal-title":"Clin Epidemiol"},{"issue":"10","key":"noi240083r37","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1161\/01.STR.0000032240.28636.BD","article-title":"Validating administrative data in stroke research.","volume":"33","author":"Tirschwell","year":"2002","journal-title":"Stroke"},{"issue":"1","key":"noi240083r38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/pds.1518","article-title":"Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data.","volume":"17","author":"Roumie","year":"2008","journal-title":"Pharmacoepidemiol Drug Safety"},{"issue":"8","key":"noi240083r39","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1161\/01.STR.0000174293.17959.a1","article-title":"Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10.","volume":"36","author":"Kokotailo","year":"2005","journal-title":"Stroke"},{"issue":"suppl 1","key":"noi240083r40","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/pds.2312","article-title":"A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data.","volume":"21","author":"Andrade","year":"2012","journal-title":"Pharmacoepidemiol Drug Safety"},{"issue":"21","key":"noi240083r41","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1161\/CIRCULATIONAHA.121.057056","article-title":"National trends and disparities in hospitalization for acute hypertension among Medicare beneficiaries (1999-2019).","volume":"144","author":"Lu","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"noi240083r42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data.","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"3","key":"noi240083r43","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1037\/a0019623","article-title":"Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research.","volume":"15","author":"Harder","year":"2010","journal-title":"Psychol Methods"},{"issue":"4","key":"noi240083r44","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1037\/1082-989X.9.4.403","article-title":"Propensity score estimation with boosted regression for evaluating causal effects in observational studies.","volume":"9","author":"McCaffrey","year":"2004","journal-title":"Psychol Methods"},{"issue":"5","key":"noi240083r45","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology.","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"issue":"7","key":"noi240083r46","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/aje\/kwq439","article-title":"Doubly robust estimation of causal effects.","volume":"173","author":"Funk","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"4","key":"noi240083r47","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40471-016-0089-1","article-title":"Methodologic issues when estimating risks in pharmacoepidemiology.","volume":"3","author":"Edwards","year":"2016","journal-title":"Curr Epidemiol Rep"},{"issue":"6","key":"noi240083r49","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/art.40798","article-title":"Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational cohort study.","volume":"71","author":"Desai","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"noi240083r50","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","article-title":"Propensity score methods for confounding control in nonexperimental research.","volume":"6","author":"Brookhart","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7","key":"noi240083r51","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1177\/0333102421989601","article-title":"Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis.","volume":"41","author":"Drellia","year":"2021","journal-title":"Cephalalgia"},{"key":"noi240083r52","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106893","article-title":"Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: a systematic review and network meta-analysis.","volume":"209","author":"Soni","year":"2021","journal-title":"Clin Neurol Neurosurg"},{"issue":"11","key":"noi240083r53","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1080\/01616412.2021.1940672","article-title":"Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine.","volume":"43","author":"Shi","year":"2021","journal-title":"Neurol Res"},{"issue":"9","key":"noi240083r54","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.tips.2016.06.002","article-title":"Wiping out CGRP: potential cardiovascular risks.","volume":"37","author":"MaassenVanDenBrink","year":"2016","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"noi240083r55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.07.002","article-title":"Ischemic stroke associated with calcitonin gene-related peptide inhibitor therapy for migraine: a case report.","volume":"28","author":"Aradi","year":"2019","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"7","key":"noi240083r56","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/phar.2706","article-title":"Myocardial infarction associated with erenumab: a case report.","volume":"42","author":"Perino","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"9","key":"noi240083r57","doi-asserted-by":"publisher","first-page":"5170","DOI":"10.1007\/s00415-022-11128-5","article-title":"Myocardial infarction in a patient with migraine and triptan overuse treated with anti-CGRP receptor monoclonal antibody: a case report.","volume":"269","author":"Cetta","year":"2022","journal-title":"J Neurol"},{"issue":"10","key":"noi240083r58","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1111\/head.14417","article-title":"Raynaud\u2019s phenomenon associated with calcitonin gene-related peptide receptor antagonists case report.","volume":"62","author":"Bedrin","year":"2022","journal-title":"Headache"},{"issue":"8","key":"noi240083r59","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/head.13596","article-title":"Raynaud\u2019s phenomenon associated with calcitonin gene-related peptide monoclonal antibody antagonists.","volume":"59","author":"Evans","year":"2019","journal-title":"Headache"},{"issue":"8","key":"noi240083r60","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4625","article-title":"Raynaud\u2019s phenomenon secondary to erenumab in a patient with chronic migraine.","volume":"9","author":"Manickam","year":"2021","journal-title":"Clin Case Rep"},{"issue":"1","key":"noi240083r61","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/0333102420950484","article-title":"Adverse effects of erenumab on cerebral proliferative angiopathy: a case report.","volume":"41","author":"Lehman","year":"2021","journal-title":"Cephalalgia"},{"issue":"2","key":"noi240083r62","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40259-024-00651-8","article-title":"Cardiovascular adverse drug reactions of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: an analysis from the European Spontaneous Adverse Event Reporting System.","volume":"38","author":"Sorbara","year":"2024","journal-title":"BioDrugs"},{"issue":"1","key":"noi240083r63","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/14740338.2023.2250720","article-title":"Adverse event profile of CGRP monoclonal antibodies: findings from the FDA Adverse Event Reporting Database.","volume":"23","author":"Wang","year":"2024","journal-title":"Expert Opin Drug Safety"},{"issue":"2","key":"noi240083r64","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s12325-022-02346-4","article-title":"Adverse events reported with therapies targeting the CGRP pathway during the first 6 months post-launch: a retrospective analysis using the FDA Adverse Events Reporting System.","volume":"40","author":"Silberstein","year":"2023","journal-title":"Adv Ther"},{"issue":"9","key":"noi240083r65","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1111\/head.14208","article-title":"Risk of hypertension in erenumab-treated patients with migraine: analyses of clinical trial and postmarketing data.","volume":"61","author":"Dodick","year":"2021","journal-title":"Headache"},{"issue":"1","key":"noi240083r66","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","article-title":"A prospective real-world analysis of erenumab in refractory chronic migraine.","volume":"21","author":"Lambru","year":"2020","journal-title":"J Headache Pain"},{"issue":"1","key":"noi240083r67","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s10194-023-01585-2","article-title":"Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients.","volume":"24","author":"Mu\u00f1oz-Vendrell","year":"2023","journal-title":"J Headache Pain"},{"issue":"4","key":"noi240083r69","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.7934","article-title":"Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with Raynaud phenomenon.","volume":"4","author":"Breen","year":"2021","journal-title":"JAMA Netw Open"},{"key":"noi240083r5","year":"2018"},{"key":"noi240083r6","year":"2018"},{"key":"noi240083r7","year":"2020"},{"key":"noi240083r8","year":"2018"},{"key":"noi240083r28","year":"2010"},{"key":"noi240083r26","unstructured":"Keisler-Starkey? K, Bunch? LN, Lindstrom? RA. Health insurance coverage in the United States: 2022. US Census Bureau. Accessed May 31, 2024. https:\/\/www.census.gov\/library\/publications\/2023\/demo\/p60-281.html"},{"key":"noi240083r27","unstructured":"US Department of Health & Human Services. Area health resources files. Accessed March 18, 2018. https:\/\/data.hrsa.gov\/topics\/health-workforce\/ahrf"},{"key":"noi240083r48","unstructured":"Cefalu? M, Ridgeway? G, McCaffrey? D, Morral? A, Griffin? BA, Burgette? L. Package \u2018twang\u2019. toolkit for weighting and analysis of nonequivalent groups. Accessed September 30, 2024. http:\/\/cran.r-project.org\/web\/packages\/twang\/twang.pdf"},{"key":"noi240083r68","unstructured":"Gill? K, Paiva da Silva Lima? G, Park? A, Urman? R, Loop? B. Hypertension and negative control outcomes in new users of onabotulinumtoxin A and monoclonal antibodies targeting the calcitonin-gene-related peptide pathway in the Marketscan Early View Claims Database. Amgen. Accessed February 28, 2024. https:\/\/catalogues.ema.europa.eu\/sites\/default\/files\/document_files\/EUPAS34832-40206.pdf"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2828333\/jamaneurology_yang_2025_oi_240083_1738707021.38254.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T11:02:07Z","timestamp":1739185327000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2828333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.4537","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}